 GSK has had a target price increase to 17 from 15.50 from Citibank following the latest judicial ruling in the Zantac case in the US, but the pharma remains only a hold even so. Following the ruling, Citi now expects a 5bn settlement compared with the 15bn settlement previously discounted. 